BRPI0408006A - uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos - Google Patents
uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticosInfo
- Publication number
- BRPI0408006A BRPI0408006A BRPI0408006-8A BRPI0408006A BRPI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A
- Authority
- BR
- Brazil
- Prior art keywords
- fatty acids
- omega
- treatment
- diabetic patients
- ethyl ester
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 title abstract 2
- 229940012843 omega-3 fatty acid Drugs 0.000 title abstract 2
- 239000006014 omega-3 oil Substances 0.000 title abstract 2
- TYLNXKAVUJJPMU-DNKOKRCQSA-N Docosahexaenoic acid ethyl ester Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(=O)OCC TYLNXKAVUJJPMU-DNKOKRCQSA-N 0.000 abstract 2
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 abstract 2
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 abstract 2
- 230000007211 cardiovascular event Effects 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 1
- 235000004626 essential fatty acids Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03004792 | 2003-03-05 | ||
| PCT/EP2004/050238 WO2004078166A2 (fr) | 2003-03-05 | 2004-03-02 | Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0408006A true BRPI0408006A (pt) | 2006-02-14 |
Family
ID=32946844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0408006-8A BRPI0408006A (pt) | 2003-03-05 | 2004-03-02 | uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1603551A2 (fr) |
| JP (1) | JP2006519244A (fr) |
| CN (1) | CN1756545A (fr) |
| AU (1) | AU2004216856A1 (fr) |
| BR (1) | BRPI0408006A (fr) |
| CA (1) | CA2515328A1 (fr) |
| MX (1) | MXPA05009432A (fr) |
| WO (1) | WO2004078166A2 (fr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| EP1834639B8 (fr) * | 2005-01-04 | 2016-12-07 | Mochida Pharmaceutical Co., Ltd. | Agent thérapeutique contre la toxicité des graisses |
| WO2006117668A1 (fr) | 2005-05-04 | 2006-11-09 | Pronova Biopharma Norge As | Analogues d'acides gras, autrement dit derives dha utilises comme medicament |
| CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
| KR101255650B1 (ko) * | 2005-05-04 | 2013-04-16 | 프로노바 바이오파마 너지 에이에스 | 새로운 ｄｈａ 유도체 및 약제로서의 용도 |
| RU2441061C2 (ru) * | 2005-05-04 | 2012-01-27 | Пронова Биофарма Норге Эс. | Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств |
| BRPI0613704A2 (pt) * | 2005-07-08 | 2011-02-01 | Mochida Pharm Co Ltd | composição para impedir o inìcio e/ou a recorrência de eventos cardiovasculares |
| JP5134916B2 (ja) * | 2005-07-08 | 2013-01-30 | 持田製薬株式会社 | 心血管イベント発症予防用組成物 |
| KR101438177B1 (ko) | 2006-11-01 | 2014-09-05 | 프로노바 바이오파마 너지 에이에스 | 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질 |
| RU2507193C2 (ru) * | 2006-11-01 | 2014-02-20 | Пронова Биофарма Норге А/С | Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar) |
| US20110166228A1 (en) * | 2006-11-01 | 2011-07-07 | Anne Kristin Holmeide | Composition |
| BRPI0718393A2 (pt) * | 2006-11-03 | 2013-11-26 | Pronova Biopharma Norge As | Álcoois de ácido graxo |
| WO2010018856A1 (fr) * | 2008-08-13 | 2010-02-18 | 持田製薬株式会社 | Agent prophylactique/d’amélioration ou thérapeutique destiné aux maladies associées au récepteur des cannabinoïdes |
| WO2010028067A1 (fr) | 2008-09-02 | 2010-03-11 | Amarin Corporation Plc | Composition pharmaceutique comprenant de l'acide eïcosapentaénoïque et de l'acide nicotinique et ses procédés d'utilisation |
| KR101383006B1 (ko) | 2009-02-10 | 2014-04-08 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| PT3278665T (pt) | 2009-04-29 | 2020-11-19 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
| CN106074486A (zh) | 2009-06-15 | 2016-11-09 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法 |
| FR2949063B1 (fr) * | 2009-08-11 | 2011-09-30 | Pf Medicament | Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| CN103338762B (zh) * | 2010-11-09 | 2015-03-25 | 持田制药株式会社 | 血糖值上升抑制剂 |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (fr) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | Méthodes de traitement de l'hypertriglycéridémie |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| EP4338805B1 (fr) | 2012-06-29 | 2025-06-04 | Amarin Pharmaceuticals Ireland Limited | Ester éthylique d'acide eicosapentaénoïque destiné à être utilisé dans la réduction du risque d'infarctus myocardique non fatal chez un sujet atteint d'une thérapie par statine |
| WO2014074552A2 (fr) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (fr) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (fr) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60248610A (ja) * | 1984-05-23 | 1985-12-09 | Nitsusui Seiyaku Kk | 糖尿病合併症の予防および治療剤 |
| GB2218904A (en) * | 1988-05-27 | 1989-11-29 | Renafield Limited | Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid |
| GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
-
2004
- 2004-03-02 WO PCT/EP2004/050238 patent/WO2004078166A2/fr not_active Ceased
- 2004-03-02 JP JP2006505440A patent/JP2006519244A/ja active Pending
- 2004-03-02 BR BRPI0408006-8A patent/BRPI0408006A/pt not_active Application Discontinuation
- 2004-03-02 AU AU2004216856A patent/AU2004216856A1/en not_active Abandoned
- 2004-03-02 CN CNA2004800055600A patent/CN1756545A/zh active Pending
- 2004-03-02 EP EP04737282A patent/EP1603551A2/fr not_active Withdrawn
- 2004-03-02 MX MXPA05009432A patent/MXPA05009432A/es unknown
- 2004-03-02 CA CA002515328A patent/CA2515328A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004078166A3 (fr) | 2004-10-28 |
| WO2004078166A2 (fr) | 2004-09-16 |
| AU2004216856A1 (en) | 2004-09-16 |
| CA2515328A1 (fr) | 2004-09-16 |
| CN1756545A (zh) | 2006-04-05 |
| JP2006519244A (ja) | 2006-08-24 |
| EP1603551A2 (fr) | 2005-12-14 |
| MXPA05009432A (es) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0408006A (pt) | uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos | |
| BR0008153A (pt) | Uso de ácidos graxos essenciais na prevenção de eventos cardiovasculares | |
| WO2009091538A8 (fr) | Composition pharmaceutique et méthode permettant de traiter l'hypertriglycéridemie et l'hypercholestérolémie chez des mammifères | |
| US5198468A (en) | Essential fatty acid composition | |
| PT1310249E (pt) | Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves | |
| BRPI0418921A (pt) | uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição | |
| WO2008018043A3 (fr) | Procédé permettant d'améliorer la santé des os et la santé musculaire | |
| DE69622722D1 (de) | Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms | |
| WO2005089744A3 (fr) | Utilisation de docosatrienes, resolvines et leurs analogues stables pour le traitement de maladies des voies respiratoires et de l'asthme | |
| CO6470839A2 (es) | Composiciones farmacéuticas que contienen epa y un agente cardiovascular y métodos de emplearlas | |
| BR0112073A (pt) | Combinações terapêuticas de ácidos graxos | |
| MXPA05003346A (es) | Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico. | |
| EP2216318A3 (fr) | Résolvines : Modèles biologiques pour les interventions thérapeutiques | |
| DE602005021668D1 (de) | Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren | |
| KR940018091A (ko) | 불포화 지방산을 포함하는 처방 | |
| YU59303A (sh) | Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca | |
| MX2010004820A (es) | Mezcla lipidica para nutricion infantil. | |
| NZ599748A (en) | Improving memory in subjects with mini-mental state examination of 24-26 | |
| WO2011097273A8 (fr) | Méthodes et compositions permettant le traitement de la stéatose hépatique non alcoolique au moyen d'acide docosahexaénoïque et de n-acétyl-l-cystéine | |
| CO6150156A2 (es) | Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares | |
| EP1765324A4 (fr) | Compositions a base de metabolites bioactifs stables d'acides docosahexanoique (dha) et eicosapentanoique (epa) | |
| BRPI0512528A (pt) | uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição | |
| Hiratsuka et al. | Effect of dietary docosahexaenoic acid connecting phospholipids on the lipid peroxidation of the brain in mice | |
| WO2006111633A3 (fr) | Utilisation de la lecithine comme medicament dans le traitement du psoriasis | |
| WO2002092779A3 (fr) | Procede d'enrichissement de tissus dans des acides gras polyinsatures a chaine longue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |